ALL3
MCID: LKM060
MIFTS: 43

Leukemia, Acute Lymphoblastic 3 (ALL3)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leukemia, Acute Lymphoblastic 3

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic 3:

Name: Leukemia, Acute Lymphoblastic 3 57
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 57 28 5 38 71
Precursor B-Cell Lymphoblastic Leukemia 71 75
Precursor B-Cell Acute Lymphoblastic Leukemia/lymphoma 58
Precursor B-Cell Acute Lymphocytic Leukemia/lymphoma 58
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 71
Precursor B-Cell Acute Lymphoblastic Leukemia 58
Precursor B-Cell Acute Lymphocytic Leukemia 58
Burkitt Lymphoma 71
B-All 58
All3 57

Characteristics:


Age Of Onset:

Precursor B-Cell Acute Lymphoblastic Leukemia: Childhood 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

OMIM® 57 615545
ICD10 via Orphanet 32 C91.0
UMLS via Orphanet 72 C0006413 C1292769
Orphanet 58 ORPHA99860
UMLS 71 C0006413 C0023485 C1292769 more

Summaries for Leukemia, Acute Lymphoblastic 3

Orphanet: 58 A rare acute lymphoblastic leukemia characterized by infiltration of bone marrow and peripheral blood by small to medium-sized blast cells typically positive for the B-cell markers CD19, cCD79a, and cCD22. Predilection sites for extramedullary involvement are the central nervous system, lymph nodes, spleen, liver, and testes. Patients present with evidence of bone marrow failure (i. e. thrombocytopenia, anemia, and/or neutropenia) and variable leukocyte count, as well as lymphadenopathy, hepatomegaly, splenomegaly, bone pain, and arthralgias.

MalaCards based summary: Leukemia, Acute Lymphoblastic 3, also known as leukemia, acute lymphoblastic, susceptibility to, 3, is related to b-lymphoblastic leukemia/lymphoma and b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), and has symptoms including bone pain An important gene associated with Leukemia, Acute Lymphoblastic 3 is PAX5 (Paired Box 5). The drugs Ifosfamide and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and t cells.

Wikipedia: 75 Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell... more...

More information from OMIM: 615545

Related Diseases for Leukemia, Acute Lymphoblastic 3

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 b-lymphoblastic leukemia/lymphoma 11.6
2 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 11.4
3 leukemia, acute lymphoblastic 11.4
4 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 11.3
5 b-lymphoblastic leukemia/lymphoma with etv6-runx1 11.1
6 b-lymphoblastic leukemia/lymphoma with hypodiploidy 11.1
7 b-lymphoblastic leukemia/lymphoma with bcr-abl1 11.1
8 b-lymphoblastic leukemia/lymphoma mll rearranged 11.1
9 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 11.1
10 b-lymphoblastic leukemia/lymphoma with il3-igh 11.1
11 b-lymphoblastic leukemia/lymphoma with tcf3-pbx1 11.1
12 b-lymphoblastic leukemia/lymphoma with iamp21 11.1
13 glycogen storage disease ii 10.9
14 agammaglobulinemia 8b, autosomal recessive 10.9
15 hemophagocytic lymphohistiocytosis, familial, 1 10.5
16 hemophagocytic lymphohistiocytosis 10.5
17 leukemia 10.5
18 sarcoma 10.4
19 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 10.3
20 children's interstitial lung disease 10.3
21 burkitt lymphoma 10.3
22 acute leukemia 10.3
23 acute erythroid leukemia 10.3
24 erythroleukemia 10.3
25 toxic encephalopathy 10.3
26 hematologic cancer 10.2
27 graft-versus-host disease 10.2
28 lymphoma 10.2
29 childhood acute lymphocytic leukemia 10.2
30 autoimmune disease 10.2
31 leukemia, acute monocytic 10.2
32 isolated growth hormone deficiency, type ii 10.2
33 prostate cancer 10.2
34 fanconi anemia, complementation group d2 10.2
35 lymphoblastic leukemia, acute, with lymphomatous features 10.2
36 myasthenia gravis 10.2
37 myelofibrosis 10.2
38 isolated growth hormone deficiency, type iii, with agammaglobulinemia 10.2
39 leukemia, acute lymphoblastic 2 10.2
40 bainbridge-ropers syndrome 10.2
41 vitamin b12 deficiency 10.2
42 interleukin-7 receptor alpha deficiency 10.2
43 isolated growth hormone deficiency type iii 10.2
44 horner's syndrome 10.2
45 hepatitis a 10.2
46 pure red-cell aplasia 10.2
47 cholestasis 10.2
48 obstructive jaundice 10.2
49 myeloproliferative neoplasm 10.2
50 acute pancreatitis 10.2

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic 3:



Diseases related to Leukemia, Acute Lymphoblastic 3

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic 3

Clinical features from OMIM®:

615545 (Updated 08-Dec-2022)

UMLS symptoms related to Leukemia, Acute Lymphoblastic 3:


bone pain

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic 3

Drugs for Leukemia, Acute Lymphoblastic 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 4 3778-73-2 3690
2
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
3
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
4
Palifosfamide Investigational Phase 4 31645-39-3 100427
5
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
6 Anti-Retroviral Agents Phase 4
7 Anti-HIV Agents Phase 4
8 Reverse Transcriptase Inhibitors Phase 4
9
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
10
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
11
Mycophenolic acid Approved, Investigational Phase 3 24280-93-1 446541
12
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643
13
Aldesleukin Approved Phase 3 110942-02-4
14
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
15
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
16
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
17
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
18
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
19
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704
20
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
23
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
24
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
25
Pegaspargase Approved, Investigational Phase 3 130167-69-0
26
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
27
Mercaptopurine Approved Phase 3 50-44-2 667490
28
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
29
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
30
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
31
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
32
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
33
Blinatumomab Approved, Investigational Phase 3 853426-35-4
34
Dasatinib Approved, Investigational Phase 3 302962-49-8 3062316
35
Ichthammol Approved Phase 3 8029-68-3
36
Tioguanine Approved Phase 3 154-42-7 2723601
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
38
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
39
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
40
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
41
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
42 Cyclosporins Phase 3
43 Interleukin-2 Phase 3
44 Analgesics, Non-Narcotic Phase 3
45
Imatinib Mesylate Phase 3 220127-57-1
46 Neuroprotective Agents Phase 3
47
Methylprednisolone Acetate Phase 3 584547
48 Antiemetics Phase 3
49 Gastrointestinal Agents Phase 3
50 Folic Acid Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 314)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
2 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
3 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4 B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) Recruiting NCT05518383 Phase 4 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
5 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Active, not recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
6 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
7 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
8 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
9 A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of (dUCB) Versus HLA-Haplo Related Bone Marrow for Patients With Hematologic Malignancies.(BMT CTN #1101) Completed NCT01597778 Phase 3
10 Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
11 Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma:a Single-center, Open-label, Pragmatic Clinical Trial Recruiting NCT05020392 Phase 3 BTK inhibitor+ Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells;Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
12 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Recruiting NCT03959085 Phase 3 Calaspargase Pegol-mknl;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
13 A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy) Recruiting NCT03914625 Phase 3 Asparaginase Erwinia chrysanthemi;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Mercaptopurine Oral Suspension;Methotrexate;Pegaspargase;Prednisolone;Prednisone;Thioguanine;Vincristine Sulfate
14 Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) Active, not recruiting NCT02101853 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Mitoxantrone;Mitoxantrone Hydrochloride;Pegaspargase;Therapeutic Hydrocortisone;Thioguanine;Vincristine;Vincristine Sulfate
15 Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) Active, not recruiting NCT01190930 Phase 3 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
16 A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations Active, not recruiting NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
17 Phase II Trial of CLAG-M in Relapsed ALL Unknown status NCT01513603 Phase 2 CLAG-M
18 Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients Unknown status NCT03142646 Phase 1, Phase 2
19 A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603) Completed NCT00849147 Phase 2
20 A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604) Completed NCT00864227 Phase 2
21 A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment Completed NCT01116193 Phase 2 Lenalidomide plus dexamethasone
22 A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma Completed NCT01700946 Phase 2 dexamethasone;vincristine sulfate;clofarabine;cyclophosphamide;etoposide;pegaspargase;methotrexate;mercaptopurine;cytarabine;mitoxantrone;teniposide;vinblastine;therapeutic hydrocortisone
23 S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia Completed NCT00945815 Phase 2 clofarabine;cytarabine
24 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
25 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
26 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
27 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
28 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
29 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
30 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
31 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
32 A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation Completed NCT00064246 Phase 1, Phase 2
33 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
34 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
35 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
36 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
37 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
38 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
39 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
40 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
41 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
42 Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia Completed NCT00039130 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;prednisone;vincristine sulfate;Allopurinol
43 Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma Completed NCT01516593 Phase 2 Induction Phase;Consolidation Phase (on day +50);Intensification phase;BEAM conditioning
44 A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma Completed NCT01842672 Phase 1, Phase 2 Clofarabine;Mitoxantrone
45 A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00073918 Phase 2 cyclophosphamide;etoposide
46 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
47 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
48 A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
49 Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas Completed NCT00001237 Phase 2 granulocyte-macrophage colony stimulating factor (GM-CSF)
50 A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas Completed NCT00058019 Phase 2 ixabepilone

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic 3

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide

Genetic Tests for Leukemia, Acute Lymphoblastic 3

Genetic tests related to Leukemia, Acute Lymphoblastic 3:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to, 3 28 PAX5

Anatomical Context for Leukemia, Acute Lymphoblastic 3

Organs/tissues related to Leukemia, Acute Lymphoblastic 3:

MalaCards : Bone Marrow, Bone, T Cells, Liver, Testes, Spleen, Myeloid

Publications for Leukemia, Acute Lymphoblastic 3

Articles related to Leukemia, Acute Lymphoblastic 3:

(show top 50) (show all 9314)
# Title Authors PMID Year
1
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. 62 57 5
24013638 2013
2
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 62 57
30643249 2019
3
Precursor B-cell acute lymphoblastic leukemia in a pediatric patient with Bainbridge-Ropers syndrome. 62
35733401 2023
4
Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. 62
36031729 2023
5
Performance comparison of systemic activity correction in functional near-infrared spectroscopy for methods with and without short distance channels. 62
36248616 2023
6
Impact of COVID 19 on erectile function. 62
35924485 2022
7
Neurochemical correlates of cognitive functions in euthymic patients with bipolar disorder: 1H-MRS study. 62
36270047 2022
8
The Value of Intraoperative Magnetic Resonance Imaging in Endoscopic Endonasal Resection of Pituitary Adenoma. 62
36393881 2022
9
Design, synthesis and biological evaluation of novel diarylpyridine derivatives as tubulin polymerisation inhibitors. 62
36196773 2022
10
Performance of cone-beam computed tomography (CBCT) renal arteriography for renal tumor embolization. 62
36399872 2022
11
Justification for initiating patiromer when restricted by prior authorization and clinical guidance in a US health care system. 62
36427342 2022
12
In silico analysis of a novel protein in CAR T- cell therapy for the treatment of hematologic cancer through molecular modelling, docking, and dynamics approach. 62
36395593 2022
13
Microwave assisted synthesis of 2-amino-4-chloro-pyrimidine derivatives: Anticancer and computational study on potential inhibitory action against COVID-19. 62
36276298 2022
14
M-Sn-Q (M = Zn, Cd; Q = S, Se) Compounds Templated by (Alkyl)ammonium Species: Synthesis, Crystal Structure, and Sr2+ Adsorption Property. 62
36395523 2022
15
Revisiting the Newly Modified Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) and Reporting Newly Identified Genes. 62
34854351 2022
16
Comparison of Ultrashort TE Lung MRI and HRCT Lungs for Detection of Pulmonary Nodules in Oncology Patients. 62
36451941 2022
17
Heterogenous Disease Course and Long-Term Outcome of Children's Interstitial Lung Disease Related to Filamin A Gene Variants. 62
35767027 2022
18
Women's experiences of a pregnancy whilst attending a specialist antenatal service for pregnancies after stillbirth or neonatal death: a qualitative interview study. 62
35853021 2022
19
A Retrospective Review of the Characteristics and Outcomes of Patients through an Integrated Palliative Care Model during the First Wave of the SARS-COV-2 Pandemic. 62
36108157 2022
20
Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. 62
35552245 2022
21
You Hurt Me, so I Hurt Myself and Others: How Does Childhood Emotional Maltreatment Affect Adolescent Violent Behavior and Suicidal Ideation? 62
35130779 2022
22
Human parainfluenza 3 and respiratory syncytial viruses detected in pangolins. 62
35678141 2022
23
Comparison of Three Approaches to Single-Port Robot-Assisted Radical Prostatectomy: Our Institution's Initial Experience. 62
36017625 2022
24
Enhanced replication fitness of MERS-CoV clade B over clade A strains in camelids explains the dominance of clade B strains in the Arabian Peninsula. 62
34918620 2022
25
SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond. 62
36130863 2022
26
Cerebrovascular accident in a child with precursor B-cell acute lymphoblastic leukemia and coronavirus disease 2019: a case report. 62
36471442 2022
27
Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia. 62
36056210 2022
28
Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition. 62
36435066 2022
29
Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac? 62
34674588 2022
30
Actinomortierella wolfii: Identity and pathology. 62
36393998 2022
31
Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. 62
35771717 2022
32
A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL). 62
36251032 2022
33
De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion. 62
36448578 2022
34
Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. 62
35622074 2022
35
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. 62
36453516 2022
36
Establishment and Verification of a Prediction Model for Identifying Pathologic Infections Based on the Clinical Characteristics of Epidermoid Cysts. 62
36374320 2022
37
Inspiratory Muscle Training and Physical Fitness in Children With Down Syndrome: A Randomized Controlled Trial. 62
35533737 2022
38
Shaking up the silence: consequences of HMGN1 antagonizing PRC2 in the Down syndrome brain. 62
36463299 2022
39
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. 62
35939781 2022
40
Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients: Results from the Spanish National Registry. 62
35947087 2022
41
Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel. 62
36116729 2022
42
Transoral Endoscopic Thyroidectomy by Vestibular Approach for Papillary Thyroid Carcinoma with Tumor Size ≥2 cm. 62
36445736 2022
43
Occurrence of familial Mediterranean fever in haemophilia patients. 62
36409293 2022
44
Comparison of Cost and Perioperative Outcomes Among Patients Undergoing Simple Prostatectomy and Laser Enucleation of the Prostate. 62
36193580 2022
45
Clinical Observation of Double Percutaneous Nephrostomy Combined with Ureter Occlusion Stent for Treating Cervical Cancer Complicated with Vesicovaginal Fistula. 62
33016777 2022
46
Prediction of exercise-induced desaturation in COPD patients without resting hypoxemia: a retrospective study. 62
36348483 2022
47
[Genetics and clinical phenotypes of epilepsy associated with chromosome 2q24.3 microdeletion]. 62
36319147 2022
48
Evaluation of a Cranial Ultrasound Screening Protocol for Very Preterm Infants. 62
36321412 2022
49
Shear wave elastography to evaluate carotid artery elasticity in long-term drinkers with varying degrees of alcoholic fatty liver disease. 62
36385468 2022
50
Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy. 62
36428756 2022

Variations for Leukemia, Acute Lymphoblastic 3

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic 3:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PAX5 NM_016734.3(PAX5):c.547G>A (p.Gly183Ser) SNV Risk Factor
88892 rs398123063 GRCh37: 9:37002702-37002702
GRCh38: 9:37002705-37002705
2 PAX5 NM_016734.3(PAX5):c.253G>A (p.Gly85Arg) SNV Likely Pathogenic
1172745 GRCh37: 9:37015151-37015151
GRCh38: 9:37015154-37015154
3 PAX5 NM_016734.3(PAX5):c.419G>A (p.Arg140Gln) SNV Uncertain Significance
1210157 GRCh37: 9:37006526-37006526
GRCh38: 9:37006529-37006529
4 PAX5 NM_016734.3(PAX5):c.22C>T (p.Pro8Ser) SNV Uncertain Significance
1691541 GRCh37: 9:37034007-37034007
GRCh38: 9:37034010-37034010
5 PAX5 NM_016734.3(PAX5):c.1013-1G>A SNV Uncertain Significance
517139 rs1554646594 GRCh37: 9:36846927-36846927
GRCh38: 9:36846930-36846930
6 PAX5 NM_016734.3(PAX5):c.1169G>A (p.Arg390His) SNV Uncertain Significance
620603 rs771002648 GRCh37: 9:36840564-36840564
GRCh38: 9:36840567-36840567
7 PAX5 NM_016734.3(PAX5):c.701T>C (p.Leu234Pro) SNV Uncertain Significance
620623 rs753068558 GRCh37: 9:36966625-36966625
GRCh38: 9:36966628-36966628
8 PAX5 NM_016734.3(PAX5):c.1013-6A>G SNV Likely Benign
802486 rs1587737218 GRCh37: 9:36846932-36846932
GRCh38: 9:36846935-36846935
9 PAX5 NM_016734.3(PAX5):c.638C>T (p.Ser213Leu) SNV Likely Benign
135001 rs137870876 GRCh37: 9:36966688-36966688
GRCh38: 9:36966691-36966691

Expression for Leukemia, Acute Lymphoblastic 3

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic 3.

Pathways for Leukemia, Acute Lymphoblastic 3

GO Terms for Leukemia, Acute Lymphoblastic 3

Sources for Leukemia, Acute Lymphoblastic 3

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....